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Abstract: Influenza is a major respiratory pathogen causing annual outbreaks and occasional 
pandemics. Influenza vaccination is the major method of prophylaxis. Currently annual 
influenza vaccination is recommended for groups at high risk of complications from 
influenza infection such as pregnant women, young children, people with underlying disease 
and the elderly, along with occupational groups such a healthcare workers and farm workers. 
There are two main types of vaccines available: the parenteral inactivated influenza vaccine 
and the intranasal live attenuated influenza vaccine. The inactivated vaccines are licensed 
from 6 months of age and have been used for more than 50 years with a good safety profile. 
Inactivated vaccines are standardized according to the presence of the viral major surface 
glycoprotein hemagglutinin and protection is mediated by the induction of vaccine strain 
specific antibody responses. In contrast, the live attenuated vaccines are licensed in Europe 
for children from 2–17 years of age and provide a multifaceted immune response with local 
and systemic antibody and T cell responses but with no clear correlate of protection. Here 
we discuss the immunological immune responses elicited by the two vaccines and discuss 
future work to better define correlates of protection. 
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Influenza continues to remain among the most important respiratory infections causing annual 
seasonal epidemics and the occasional pandemic. Influenza virus causes an estimated annual global toll 
of 500,000 deaths and 1 billion severe illnesses and an estimated $ 8 billion in annual economic cost of 
influenza in the US alone [1]. 
Among the various public health strategies in place to combat influenza, vaccination is the most  
cost-effective strategy against annual seasonal influenza. Inactivated “killed” influenza vaccines have 
been in use since the 1940s with improvements primarily made in production technologies and use of 
adjuvants. An alternative type, live attenuated influenza vaccine, has been in use in Russia for over  
50 years and in 2003 was licensed for use in North America. More recently, Europe has licensed this 
vaccine and recommended its use in children from 2–18 years of age. Although this new live attenuated 
influenza vaccine (LAIV) has been in development since the 1970s and extensive data on safety and 
efficacy is available, the immunological mechanisms of action and correlates of protection remain 
unclear. Here we review our current understanding of the efficacy of LAIV in humans, compare trivalent 
inactivated influenza vaccine (TIV) to LAIV and highlight the key research questions that will impact 
immunization policies with LAIV. 
2. Epidemiology of Influenza 
There are three types of influenza virus (A, B and C), which differ in their epidemiology, 
pathogenicity, antigenicity and genome organization. Type A is the most common type found in a wide 
variety of birds and mammals, while types B and C are predominantly human pathogens. Influenza A 
virus is further subdivided into different subtypes based on antigenic differences in the surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA). Annual seasonal influenza epidemics are 
caused by subtypes of Influenza A and Influenza B viruses while Influenza A viruses are responsible for 
influenza pandemics. 
Influenza is an enveloped negative sense segmented RNA virus with two surface glycoproteins and 
nine internal proteins (Figure 1). The surface glycoproteins, HA and NA enable attachment, entry and 
egress of the virus from infected cells. The HA trimer protein has a globular head region with sialic acid 
receptor binding sites that enable attachment to host cells. Mutations in these receptor-binding sites on 
the globular head are responsible for the antigenic variation that generates drift variant virus strains 
responsible for seasonal outbreaks of influenza. At unpredictable intervals, different subtypes of 
influenza A virus undergo gene reassortments to give rise to a novel virus strain that is capable of causing 
pandemics in the immunologically naïve population. Once a pandemic virus emerges, it usually replaces 
the previously circulating Influenza A strain of the same subtype, as seen with the 2009 H1N1pdm09 
virus. In addition, avian influenza viruses, e.g., H5N1 or H7N9 can cause human infection following 
close contact with infected poultry but to date remain non-transmissible between humans. 
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Children and the elderly are at particularly high risk of developing severe disease following influenza 
infection. Severe disease with influenza is usually manifest by respiratory failure, acute respiratory 
distress syndrome (ARDS) and secondary bacterial pneumonia. In addition to these traditional high-risk 
groups, asthmatics, those with chronic lung disease, those with liver disease, immunosuppressed 
individuals, pregnant women and diabetics are also considered high-risk target groups. These groups are 
targeted for immunization by annual vaccination programs. 
 
Figure 1. The structure of Influenza A virus and the ribonucleoprotein complex. The virus 
proteins are denoted as HA hemagglutinin; NA neuraminidase, M1 matrix protein 1;  
M2 matrix protein 2; NP nucleoprotein; and the polymerase proteins PA, PB1 and PB2. 
3. Vaccine Design and Recommendations 
Seasonal influenza vaccines are composed of virus strains representative or antigenically similar to 
those circulating in the population for that season. Traditionally influenza vaccines have been trivalent 
to cover Influenza A H3N2, H1N1 and influenza B strain. The circulation of two lineages of  
influenza B has led to development and licensing of quadrivalent vaccines containing both influenza B 
lineages. However, in order to achieve this, experts need to predict the circulating strain in order to make 
the vaccine for the upcoming season, in part because influenza vaccines are predominantly produced in 
embryonated hen’s eggs which takes approximately 6 months. In February every year an expert panel 
that includes the World Health Organization (WHO) reviews Southern hemisphere data and decides on 
the circulating strains for the subsequent influenza season in the Northern hemisphere. Manufacturing 
of vaccines is initiated in March incorporating the strains recommended by the WHO. A major limitation 
of this approach is the dependence on the influenza viruses not undergoing antigenic change (drift or 
shift). Ever so often, new antigenic drift variants emerge to which the vaccines are poorly matched such 
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as the influenza A H3N2 in 2014–2015 season in the Northern hemisphere. In such cases, vaccine 
efficacy has been shown to be 50% lower depending on the degree of the match [2]. Moreover, if 
pandemic strains emerge, manufacture is not rapid enough to produce vaccines against these new strains. 
Thus, there have been significant efforts into developing better ways to predict antigenic change in 
influenza viruses, developing new techniques to reduce manufacturing time, developing universal 
vaccines that are effective against a broad range of viruses and developing vaccine stockpiles. 
Annual influenza vaccination recommended for target groups are either inactivated vaccines or, more 
recently, live attenuated vaccines (Figure 2). Inactivated vaccines are either split virus, subunit vaccines 
or recombinant HA based vaccines that are administered parenterally. The vaccines are standardized 
according to the quantity of hemagglutinin, commonly 15 μg HA per strain, although high dose vaccines 
have recently been licensed for the elderly containing 60 μg HA per strain [3]. Adjuvants like oil in water 
(MF5 and AS03) increase the immunogenicity of the vaccine and are particularly used in the elderly, 
and for pandemic vaccines to spare doses [4]. Inactivated vaccines have an excellent safety profile, are 
recommended for children from 6 months of age, the elderly, asthmatics and those with other high risk 
conditions (Table 1). 
 
Figure 2. The different formulations of influenza vaccine. Currently licensed influenza vaccines 
are predominately inactivated virus (whole inactivated, split, subunit or virion like particle) 
or live attenuated influenza vaccine. Novel vaccines are DNA or synthetic peptide vaccines. 
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Table 1. The World Health Organization Strategic advisory committee influenza vaccine 
recommendations in prioritized order. 
Recommended Group WHO Rationale for the Recommendation 
Pregnant women 
Increased risk of serious disease in mother 
Increased risk of death in mother and unborn child 
Secondary effect of protection of child up to 6 m 
Globally applicable * 
Healthcare workers 
Increased exposure to influenza 
Reduces morbidity and mortality in patients 
Preserves integrity of health care systems 
Possible to implement 
Children <2 years old 
Experience highest levels of serious illness 
Responsible for spread in community 
Disadvantage costly to implement vaccination campaign 
Children 2–5 years old 
Large burden of morbidity 
Respond better to vaccines than younger children 
live attenuated influenza virus (LAIV) gives improved protection 
Children < 6 months 
No available vaccines 
Indirect protection through vaccination of mother during pregnancy 
Indirect protection through vaccination of close contacts 
Elderly > 65 years old 
Highest risk of mortality 
Vaccine is less effective 
Disadvantage annual immunization is costly to administer 
Patients with chronic conditions 
Highest risk for serious disease 
Disadvantage requires considerable resources to identify individuals 
* pregnant women have contact with health care services. 
In contrast, intranasally administered live attenuated influenza vaccines are produced by reverse 
genetics using the HA and NA genes from circulating viruses on an attenuated, temperature-sensitive, 
cold adapted virus backbone. This backbone prevents replication at temperatures above 33 °C, thereby 
restricting replication to the upper but not lower respiratory tract [5,6]. Although the master donor 
backbone varies between the different manufacturers of the LAIV vaccine, the safety profile of this 
vaccine in immunocompetent adults and children is good, and multiple studies have demonstrated the 
genetic stability of the live vaccine virus strains [7]. Once administered, vaccine virus can be isolated from 
nasal secretions up to 7 days post-vaccination in young children, but is rarely observed for longer than 
14 days post-vaccination, and secondary transmission of the virus to close contacts is uncommon [8].  
In the US and Canada, this vaccine is recommended for children from 2 years of age and for healthy 
adults up to 49 and 59 years of age, respectively. In Europe, the recommendation is limited to children 
2–18 years of age [9]. In immunologically naïve subjects (e.g., children <9 years old, who have not been 
previously vaccinated with influenza) two doses of vaccine are recommended at minimum of 4-week 
interval. In children 2–8 years old who have previously been vaccinated or children (>8 years old) and 
adults, one dose of vaccine is recommended. The LAIV is preferentially recommended for vaccination 
of children in some countries such as the UK where it is included in the childhood vaccination program 
and in Germany [10], although it was recently removed from preferential recommendation in the USA 
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after poor efficacy had been observed against the Influenza A H1N1 and drifted H3N2 strains [11]. 
However, this live virus vaccine is not recommended for children under 2 years of age, in the elderly, 
those immunosuppressed and those caring for people with high risk of severe influenza disease. Also, 
LAIV is contraindicated in severe asthmatics currently on oral or high dose inhaled glucocorticosteriods 
or active wheezing. In early studies, when the live virus was administered in children under 2 years of 
age, an increase in wheezing was observed in vaccinated children, which underlies the rationale for not 
recommending the vaccine for under 2-year-olds [12] (Table 2). 
Table 2. LAIV is contraindicated in the following people. 
Children General Contradictions in all Groups 
< 24 months of age 
Receiving aspirin or aspirin-containing therapy 1 
Hypersensitivity to gelatin, gentamicin or ovalbumin 
Pregnant women in USA and Canada 
Older adults (USA >50 & Canada >60 years old) 
 
Clinical immunodeficiency due to conditions or 
immunosuppressive therapy 2 
1 Association of Reye’s syndrome with salicylates and wild-type influenza infection; 2 acute and chronic 
leukemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids. 
4. Natural Immunity To Influenza 
Exposure with influenza virus initiates a cascade of humoral and cellular immune responses to resist 
infection and development of symptoms. Understanding these protective immune responses and the 
mechanisms by which they are induced are critical for the development of new improved vaccines that 
attempt to induce such protective responses. 
The primary mediator of protection against infection is neutralizing antibodies targeting the HA. 
These antibodies are predominantly targeted against the receptor-binding sites in the distal globular head 
region of the virus thereby preventing attachment of the virus to host cells. The measurement of HA 
specific antibodies by the Hemagglutination-Inhibition (HAI) and Microneutralization (MN) assays 
remains the primary correlate of protection against influenza and current influenza vaccines are designed 
to induce such strain-specific antibodies [13]. In contrast to such strain-specific antibodies, antibodies 
targeting the highly conserved membrane proximal stalk region of HA have been recently shown to 
mediate protection against a broad range of viruses [14,15]. This broad cross-strain protection is 
particularly important as new virus strains emerge to which host neutralizing antibodies are less effective. 
Although the exact mechanisms by which these stalk-specific antibodies mediate protection is unclear, 
prevention of fusion, preventing release of viral progeny and antibody-dependent cellular cytotoxicity 
(ADCC) may account for their protective effect. Antibodies to other viral proteins such as NA and M2e are 
also involved in mediating protection although their exact contribution remains unclear. Anti-NA antibodies 
have been shown to protect against development of illness following natural infection and following 
experimental challenge [16,17]. However, the assays to measure these antibodies are technically difficult 
to standardize and work is ongoing to standardize assays to measure these antibodies. Anti-M2e 
antibodies constitute a particularly attractive target for vaccine development, as M2e is a highly 
conserved protein on the viral surface to which antibodies can be targeted. In animal models, antibodies 
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to M2e have been shown to mediate protection against lethal influenza [18], although the role for these 
antibodies in protection in humans remains to be confirmed. 
In contrast to antibodies, T-cells can protect against development of symptomatic disease when 
antibody mediated protection against infection is circumvented. The role of T-cells in mediating 
protection has been extensively demonstrated in animal and non-human primate models [19,20]. In 
experimental challenge models in humans, pre-existing CD4+ and CD8+ T-cells were shown to be 
associated with reduced viral shedding and symptoms [21,22]. More recently, we have identified CD8+ 
T-cells of a late-effector (CD45RA+CCR7−) phenotype to be associated with protection against 
symptomatic influenza [23]. Critically, these T-cells are capable of recognizing epitopes on internal 
proteins that are highly conserved across different influenza viruses. The role of CD4+ T-cells in 
mediating protection against influenza is becoming increasingly evident. CD4+ T-cells are capable of 
direct cytotoxic killing of virus-infected cells as well as providing help to CD8+ T-cells [24]. A new 
subset of CD4+ T-cells, T follicular helper cells (TFH) have been described which are vital in B cell help, 
germinal center formation and induction of antibodies after infection and vaccination [25].  
A key requirement for mediating protection against influenza is the necessity for immune mediators 
to be present at the site of infection—the respiratory tract. Mucosal IgA antibodies induced following 
infection and intranasal vaccination correlate with protection against infection in experimental human 
challenge models of influenza [26]. Mucosal T-cells mediate protection against influenza in animal 
models, although their role in humans is less clear. Mucosal T-cells include T-cells in the airway,  
lung-migrating memory T-cells and lung-resident memory T-cells have been demonstrated to mediate 
protection in animal models of influenza [27–29]. 
Natural infection is able to induce this multifaceted mucosal and systemic immune response to confer 
protection against subsequent influenza infection with similar strains. Thus, the challenge for an effective 
influenza vaccine is to mimic natural infection in conferring protection against influenza. 
5. Inactivated Influenza Vaccines (IIV) 
Inactivated influenza vaccines (IIV) have been in production and in use since the 1940s and are the 
most common type of influenza vaccines produced and used. These vaccines primarily contain HA and 
NA proteins with some preparations containing some NP protein with or without an accompanying 
adjuvant. Meta-analyses have found inactivated vaccines to show ~60% efficacy in children and ~40% 
efficacy in adults and the elderly [2,31], although a more recent meta-analysis with stringent inclusion 
criteria for trials found lower levels of efficacy than previously reported [32]. 
Previously the European Medicines Agency (EMA) committee for Medicinal Products for Human 
use (CHMP) required vaccine manufacturers to conduct clinical trials each year to examine the tolerability 
and immunogenicity measured by the HAI assay for annual updating of seasonal IIV [33]. In 2015 these 
guidelines were changed to no longer require clinical trials for strain changes of licensed IIV [34].  
The evidence for use of HAI titers as a surrogate correlate of protection comes from human challenge 
and infection studies. In human challenge studies, pre challenge serum HAI titer of 18–36 was associated 
with 50% protection from infection [35]. A clear relationship between HAI titers prior to infection and 
the percentage of people infected was found in subsequent studies with viral [36] and attenuated viral 
challenge [37] and in a recent meta-analysis [38]. These studies support the use of evaluation of serum 
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HAI antibody responses as a surrogate correlate of protection in adults for investigating vaccine 
responses. However in children despite a correlation between the presence of HAI antibody and 
protection from infection with the same strain [39], higher HAI titers of 110 were required for 50% 
protection [40]. The HAI assay is a technically simple assay to perform relying on the ability of HA 
specific antibodies to inhibit the binding of HA to red blood cells, however international standardization 
studies have shown that there is large variation in HAI titers (8–128-fold) between laboratories [41–44]. 
Therefore, there is a need to define the HAI titers associated with laboratory confirmed influenza (virus 
culture or PCR positive) in all populations which could be used in evaluation of vaccines responses and 
importantly to define HAI titers associated with protection to pandemic strains. 
Vaccination with IIV results in both local and systemic immune responses. The serum antibody 
response increases as early as 2–6 days after seasonal inactivated influenza vaccination in primed 
subjects [45] and peaks at approximately 2 weeks after vaccination when 90% of vaccinees have 
protective antibody titers [45,46] The durability of antibody responses following IIV is not clear. The 
serum antibody response then wanes over time and is generally two-fold lower 6 months after 
vaccination [47], although absolute titers seem to be maintained above the protective threshold. A 
seminal study investigating the durability of protection after vaccination and correlating this with 
antibody responses found that although there was a decline in the antibody responses within 8 months 
after IIV, although individuals were still protected against experimental challenge from a live attenuated 
homologous virus [48]. 
The serum antibody response is dominated by the IgG, particularly IgG1, isotype of antibodies with 
lower concentrations of IgM and IgA. Influenza-specific antibody-secreting cells (ASC) appear in the 
circulation at approximately 7 days post seasonal influenza vaccination, earlier than serum antibody 
response [45] and consist predominantly of IgG and IgA. In young children (2 to 3 years old), previous 
natural priming by influenza infection was essential to mount strong antibody and antibody secreting 
cell responses in the peripheral blood [49,50] after inactivated vaccine. In these children, peak ASC 
response was observed 7 days after the first dose and 4–6 days after the second vaccine dose. In healthy 
adults, high numbers of influenza specific antibody secreting cells (ASC) are present in the nasal mucosa 
but the numbers remain stable after inactivated vaccination [51]. However, a rapid transient increase in 
specific ASC is observed in the tonsils and peripheral blood after parenteral vaccination [45,52]. Generally 
peak ASC numbers elicited after parenteral vaccination do not correlate with subsequent antibody 
responses [45,53]; although one detailed study found a correlation [54]. Whether this is a function of 
timing of measurement of antibody responses or if long lived plasma cells rather than ASCs may be a 
better correlate of antibody responses or whether the quality of antibody responses rather than peak titers 
may be a better readout remains to be understood. Investigating the somatic mutation status of the 
immunoglobulin heavy chain variable genes in plasmablasts would provide insight into the origin of the 
response as mutations progressively accumulate on variable genes after repeated immunizations [55]. 
Plasmablasts with a high number of somatic mutations have undergone extensive affinity maturation and 
selection, suggesting reactivation of memory B cells. Whilst plasmablasts with lower mutational 
frequencies are probably indicative of a primary response. Detailed bioinformatics analyses into the 
immunoglobulin gene repertoire could provide an in-depth insight into B cell dynamics driving the 
evolution of antibody responses. 
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In the tonsils, this is associated with a significant decrease in both naïve/effector (CD45RA+) and 
memory (CD45RO+) CD4+ cells upon vaccination [56]. Upon antigen re-encounter, memory B cells 
(MBC) differentiate into plasmablasts secreting IgG antibodies and undergo secondary affinity maturation 
to drifted influenza epitopes. Early HAI antibody responses after pandemic H1N1 vaccination provide 
an indicator of the long-term protective memory B cells response (CD3-CD19+CD20+CD27+) after a 
booster vaccination in low responders [53]. 
Interestingly, recent work investigating the plasmablast response to IIV found a lower induction of 
plasmablasts and plasmablast-derived polyclonal antibodies to homologous and heterologous HA 
proteins following IIV compared to LAIV [57]. A recent study has found a reduced number of lineages 
of antibody repertoire in elderly people compared to younger individuals, suggesting a reduced pool of 
antibody lineages for reactivation upon vaccination [58]. The use of systems biology to examine early 
molecular signatures after vaccination, found that expression of kinase CaMKIV at day 3 after IIV, 
inversely correlated with subsequent antibody titers [59]. 
The response of classical CD4+ and CD8+ T-cells following IIV is less clearly understood. Cross-priming 
by inactivated vaccines to induce MHC-Class I restricted CD8+ T-cells has been demonstrated in animal 
models. Data from clinical trials investigating the induction of antigen-specific CD8+ T-cells after 
inactivated vaccination have reported mixed results. He and colleagues reported no increase in 
CD8+IFNg+ T-cells after vaccination in adults or children [60,61]. However, other investigators have found 
an increase in CD8+IFNg+ T-cells following vaccination specific to the HA protein or live virus [62,63]. 
Our work has shown no increase in CD8+ T-cells after parenteral inactivated vaccination in adults 
(unpublished data). CD4+ T-cells play a key role in anti-influenza immunity both in direct killing 
through intrinsic effector mechanisms and by stimulating cells of the adaptive or innate immune system. 
In contrast to CD8+ T-cells, the influenza-specific Th1 CD4+ T-helper cell response to vaccination 
increases following vaccination, albeit the durability of this response is less clear. The influenza-specific 
CD4+ T helper (Th) 1 cell response was positively correlated with the long-term IgG MBC response, 
suggesting a role for this T-cell subset in mediating the long-lived MBC response [55]. More recently, 
work has focused on a particular subset of CD4+ T-cells, T-follicular helper cells that are critical to 
germinal center formation and B cell help. Two recent papers have shown that the induction of 
CD4+CXCR5+ TFH cells following IIV was associated with the rise in antibody response, although  
the phenotype of these circulating TFH cells identified to correlate with antibody induction were 
different [64,65]. 
Novel adjuvants such as proprietary oil-in-water emulsions (AS03, MF59) have shown great potential 
for pandemic vaccines with antigen dose-sparing and augmenting immune response to homologous and 
cross-reactive strains after H5 vaccination [66]. 
6. Live Attenuated Influenza Vaccine (LAIV) 
An alternative vaccine is the LAIV that is licensed for use in the US, Europe, Russia and India. LAIV 
is more efficacious in children compared to IIV with meta-analysis reporting up to 80% efficacy in 
children below 6 years of age to matched strains and 40% efficacy in adults [2,30]. LAIV is administered 
intranasally and may elicit a longer-lasting, broader immune (humoral and cellular) response, which 
more closely resembles natural immunity after infection (Figure 3). The use of an intranasal influenza 
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vaccine has clear potential benefits over traditional parenteral administration of the vaccine, particularly 
in children e.g., long lasting effect, ease of administration, and compliance rates and provides a more 
appropriate immune response mimicking natural infection. 
 
Figure 3. Model of induction of immune responses after live attenuated influenza 
vaccination (LAIV). (1) Intranasal LAIV immunization; (2) Viral antigen is transported to 
the tonsils/adenoids by the Dendritic Cells (DCs); (3) Activation and proliferation of T and 
B cells in tonsils/adenoids with help from CD4+ T-cells. Affinity maturation of B cells;  
(4,5) Activated T and B cells home to site of infection and enter circulation. Plasma cells 
secrete antibody into the blood and at the mucosal surfaces. 
In contrast to IIV, LAIV induces a more multifaceted response with induction of serum HI, IgG, 
neutralizing antibody and neuraminidase antibody, local IgA and antigen-specific cytokine-secreting  
T-cells. LAIV must replicate in the upper respiratory tract to elicit an immune response, therefore the 
presence of pre-existing antibodies or cross-reactive T cells could inhibit virus infection and replication. 
The systemic strain-specific antibody and T-cell responses induced by LAIV in children are maintained 
for up to 1 year after vaccination [67]. A large field study found that the majority of subjects with high 
IFN-γ secreting cells (≥ 100 spot forming cells per million lymphocytes) were protected from influenza 
infection [68], but whether these responses were CD8+, CD4+ or NK cells was unclear. Interestingly, 
Hoft and colleagues demonstrated that LAIV but not IIV was able to induce CD8+ T-cells and 
gamma/delta T-cells in young children [69] while others have reported an increase in NK cells following 
influenza vaccination [62]). Mucosal antibodies are thought to be associated with protection [26,70], 
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although a quantitative correlate does not exist in part because of the difficulty in sampling and assaying 
mucosal antibodies [26]. At present there are no known correlates of protection after LAIV and because 
of this lack of a suitable correlate of protection to aid in licensing of the LAIV, the CHMP requires animal 
challenge studies for annual licensing of LAIV [34]. These studies are conducted to show that LAIV 
significantly decreases the challenge virus in the upper respiratory tract infection as well as preventing 
replication of a circulating virus in the lungs. Future studies of LAIV should focus on defining the 
immunological mechanism of protection. The hope is that with the next generation of immunology integrated 
with systems biology we will gain further understanding of the mechanism of protection of LAIV. 
7. Conclusions 
The two main types of influenza vaccines induce fundamentally different immune responses and may 
have different mechanisms of protection (Table 3). IIVs are safe and effective against homologous 
vaccine and are recommended for children from 6 months old mediating protection through antibodies 
directed at the HA surface glycoprotein. The intranasal LAIV, recommended for children above the age 
of 2 years, induces a broader immune response wherein protection is not antibody mediated and probably 
involves undefined multiple correlates of protection. At present the two major hurdles to the widespread 
use of LAIV are its contraindication in some risk groups and the lack of immunological correlates of 
protection. The development of the next generation influenza vaccines require increased understanding 
of immune responses to current vaccines and infection with further evaluation of immunological 
correlates of protection. It is clear that the immune response and therefore correlates of protection may 
differ according to the vaccine type and formulation, age of the recipient and health status, and, therefore, 
the idea that one size fits all may not be appropriate. 
Table 3. Comparison of the immune response to inactivated influenza and live attenuated 
influenza vaccine.  
 Inactivated Influenza Vaccine Live Attenuated Influenza Vaccine 
HAI response +++ + 
Antibody secreting cells ++ + 
Memory B cells + + 
Nasal IgA −/+ +++ 
NA antibody −/+ ++ 
CD4 T cells ++ +++ 
CD8 T cells − +? 
Cross protective immunity −/+ ++ 
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